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Abstract Ipilimumab is a monoclonal antibody that
blocks cytotoxic T-lymphocyte antigen4 (CTLA-4), an
inhibitory molecule typically expressed on T cells.
Blockade of CTLA-4 induces an overall activation of T
cells, including an immune-mediated anti-tumour response.
Unfortunately, this broad T cell stimulation also causes
immune-related adverse events (irAEs), such as dermatitis,
colitis, hepatitis and hypophysitis. Ipilimumab is currently
available in Belgium as a second line of treatment for
patients with advanced melanoma, and is used at a dose of
3 mg/kg of body weight, although higher doses were pre-
viously used (up to 10 mg/kg). We performed a retro-
spective analysis to identify melanoma patients treated
with ipilimumab at the Ghent University Hospital between
2010 and 2013. Data on symptoms, stage and timing of
ipilimumab, response and adverse events were collected
with a special attention to endocrine disturbances, going
from a limited involvement of one endocrine axis to
development of a hypophysitis. We identified a total of 39
patients with stage III (No. = 7) or stage IV (No. = 32)
melanoma, who received a dose of 3 (No. = 31) or 10
(No. = 8) mg/kg. Six patients developed a severe form of
irAEs, including one case of colitis (2 %), one case of
sarcoidosis (2 %) and 4 cases (10 %) of hypophysitis.
Hypophysitis developed between the second and fourth
cycle of ipilimumab administration and was independent of
the dose used. We describe four cases of involvement of
the pituitary gland during treatment with ipilimumab.
When managed with vigilant monitoring and high-dose
corticosteroids, the acute symptoms resolve, but lifelong
hormone substitution therapy can be necessary. Involve-
ment of the pituitary axes is a severe side effect of treat-
ment with ipilimumab with an urgent need for the correct
medical intervention.
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Introduction
Melanoma, currently representing 10 % of all skin cancers,
is an aggressive disease with increasing incidence and a
one-year survival from 30 to 60 % in advanced stages.
Frequently, young people are affected. The estimated age-
standardized rates of new melanoma cases for 2012 were
11.4 per 100,000 for males and 11.0 per 100,000 for
females [1]. The male/female ratio of melanoma varies
among different countries and among age groups. A male
predominance has been recorded in countries with a high
melanoma incidence, such as Australia and the United
States. The majority of Western and Northern European
countries report higher incidence rates in females versus
males, whereas in most Central, Eastern and Southern
European countries melanoma predominates in men [1].
For the age groups \44 years, females show higher inci-
dence rates, with the peak difference in the age group
20–24 years. Males exhibit higher incidence rates after the
age of 44 years [2]. Patients diagnosed at an early stage can
usually be treated with surgical excision with curative
intent, and only a minority of these patients will develop
metastatic disease [3, 4]. The lifetime risk of developing
melanoma is estimated to be 1 in 50 individuals [5].
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For decades, patients with advanced melanoma were
treated with dacarbazine (DTIC) or high-dose interleukin-2
(IL-2), but remission rates were low and toxicity high. Due to
development of alternative treatment approaches, such as
immunotherapy (anti-CTLA4 and anti- programmed death-
1/anti- PD-Ligand) and targeted therapy (Rapid accelerating
fibrosarcoma type B oncogene (BRAF) inhibition, extra-
cellular Signal-regulated Kinase Kinase (MEK) inhibition,
neuroblastoma RAS viral oncogene homolog (NRAS)-
inhibition [4, 6]), treatment of patients with advanced mel-
anoma has improved significantly. For the first time in years,
an overall survival benefit was demonstrated.
This paper will focus on hypophysitis secondary to
ipilimumab, an adverse event that has been reported in
clinical trials at incidences ranging from 0 to 17 %. The
clinical presentation can vary from a disturbance of one
axis to development of an adenohypophysitis. Involvement
of the pituitary axes can be potentially life-threatening with
an urgent need for a correct medical intervention. There-
fore, it is important to monitor this clinical problem and
start treatment whenever necessary despite the infrequent
presentation.
Ipilimumab is a monoclonal antibody against cytotoxic
T-lymphocyte antigen4 (CTLA-4). The CTLA-4 receptor,
present on T lymphocytes, works as a negative regulator of
T cell activation, causing a physiological interruption of
the activated immune system. Ipilimumab blocks CTLA-4,
causing activation of cytotoxic lymphocytes, which results
in an immune-mediated anti-tumour response [7–9].
Hodi et al. [10] presented data on efficacy in 2010. In a
large clinical trial (n = 676), the median overall survival
was 10.0 months for patients receiving the combination of
ipilimumab and gp100 peptide vaccine compared with
6.4 months among those receiving gp100 alone (hazard
ratio for death, 0.68; P \ 0.001). The overall survival for
patients receiving ipilimumab alone was 10.1 months
(hazard ratio for death compared to the gp100 vaccine
alone was 0.66; P = 0.003). However, there were more
grade 3 and 4 immune-related adverse events observed in
patients treated with ipilimumab (10 to 15 %) as compared
with gp100 alone (3 %).
Due to immunostimulation, autoimmunity is a known
treatment-related problem, resulting in immune-related
adverse events (irAEs) in a significant number of patients
[7, 8]. The most common autoimmune adverse events are
dermatitis with rashes, colitis, hepatitis and hypophysitis.
Even development of sarcoidosis has been described.
Pancreatitis, iridocyclitis, lymphadenopathy, nephritis and
neuropathies have also been described. Sometimes, the
adverse events can be potentially life-threatening with an
urgent need for medical intervention. An example of a life-
threatening adverse event is involvement of the pituitary
gland [9, 11].
Ipilimumab was approved for the treatment of mela-
noma by the Food and Drug Administration (FDA) in
March 2011 and by the European Medicines Agency in
July 2011 for use in advanced (unresectable or metastatic)
malignant melanoma [7, 11]. The recommended dose and
schedule is 3 mg/kg by intravenous infusion given every
3 weeks for four doses.
Materials and methods
We performed a retrospective analysis of the Ghent Uni-
versity Hospital medical records to identify melanoma
patients treated with ipilimumab between 2010 and 2013.
Of the total 2616 patients seen at our department in this
time period, 215 were seen for melanoma, and of them 39
received ipilimumab at a dose of 3 (No. = 31) or 10 mg/kg
(No. = 8).
Data on symptoms, stage of disease, dose and timing of
ipilimumab, response and adverse events were collected.
Results
Of the 39 patients treated with ipilimumab, 7 patients had
stage III disease, 32 stage IV. Six patients developed a
severe adverse event that led to discontinuation of the
treatment. Among these 6 patients, 4 patients presented
with involvement of the pituitary axis, going from
involvement of one or more pituitary axes. Furthermore, 1
of the 6 patients presented with a sarcoidosis and 1 patient
with colitis. Regarding involvement of the pituitary axes,
we report an onset of symptoms between the second and
the fourth cycle of treatment, for doses of 3 mg/kg (n = 2)
and 10 mg/kg (n = 2) as well. Here, we describe four cases
of hypophysitis. (Symptoms are described following the
Common Terminology Criteria for Adverse Events
(CTCAE). An overview of clinical picture, hormonal val-
ues, initial therapy and follow-up is reported in Tables 1, 2.
Hypophysitis with failure of the thyroid gland,
the adrenal and gonadal axis
In January 2010, a 56-year-old patient was diagnosed with
a non-ulcerating malignant melanoma on the right hypo-
chondrium with a Breslow thickness of 2 mm. A broad
resection with sentinel procedure was performed. Stage
was pT1apN1cM0.
In May 2010, the patient was included in the adjuvant
study with ipilimumab (dose 10 mg/kg). Two months after
the initial dose of ipilimumab, she complained of severe
headache, asthenia and diminished libido. Hormonal
investigations showed a failure of the thyroid, adrenal and
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Table 1 Clinical characteristics
Case 1 Case 2 Case 3 Case 4
Gender Female Male Male Male
Age 56 31 81 78
TNM stage pT1aN1cM0 pT3bN2M0 pT2aN0M0 Stage IV
Dose 10 mg/kg 10 mg/kg 3 mg/kg 3 mg/kg
Indication Ipilimumab Adjuvant Adjuvant Metastatic disease Metastatic disease
# Cycle onset symptoms 2 4 3 2
Diagnose Hypophysitis with failure of
thyroid, adrenal and gonadal
axis
Hypophysitis with
failure of
adrenal axis
Hypophysitis with failure
of thyroid and adrenal
axis
Hypophysitis with
failure of thyroid and
adrenal axis
Treatment L-Thyroxine ? Hydrocortisone
? Dehydroepiandrosterone
Hydrocortisone L-Thyroxine ?
Hydrocortisone
L-Thyroxine ?
Hydrocortisone
Follow-up (D time onset
symptoms—last
consultation)
24 m (Disease free) 17 m (PD) 3 m (PD) 6 m (PD)
Key clinical characteristics of four patients with advanced melanoma who received ipilimumab and developed secondary hypophysitis
PD progressive disease
Table 2 Overview symptoms, hormonal values, initial therapy and follow-up
Patient 1 2 3 4
Start Ipilimumab 18/5/2010 30/11/2010 7/10/2010 7/12/2012
Onset endocrine AE 2/7/2010 04/2011 12/2010 14/1/2013
Symptoms (Grade III–IV
CTCAE)
Headache asthenia
diminished libido
Fatigue muscle weakness
pain Diarrhoea
Hypotension
Lethargy adynamia Headache photophobia
phonophobia
Hormonal values Onset FU (27/7/2011) Onset FU (01/2011) Onset FU (02/11) Onset FU (07/2013)
ACTH/lg/dL (\46) \5 \1 \5 \5 NA NA 14 NA
DHEA/lg/dL* 18.76 3.4 NA 51.33 NA 13.61 NA NA
Cortisol**/lg/dL 0.4 \0.2 1.1 0.1 4.6 47.6 0.9 NA
TSH/lU/mL (0.27–4.2) 0.025 3.67 1.4 3.5 \0.002 0.038 0.19 NA
GH/ng/mL (\8) 0.68 NA 5 \0.05 NA NA NA NA
FSH***/mU/mL 4.9 25.5 2.9 2.9 0.63 1.1 6.2 NA
LH****/mU/mL 0.59 11.4 2.4 2 0.64 1.4 1.1 NA
Supportive medication (Start) Levothyroxine 75
hydrocortisone 15–10–
15 mg
Hydrocortisone 15–10–5 Levothyroxine 75
hydrocortisone 15–10–5
Levothyroxine 75
hydrocortisone
15–10–5
Supportive medication
(Follow-up)
DHEA-s 2.5
hydrocortisone 15–10–
2,5
Hydrocortisone 15–10–5 Levothyroxine 100 Levothyroxine 75
methylprednisolone
32
Co-medication Paracetamol
paracetamol ? coffeine
None Allopurinol
hydroxyethylrutosiden
fesoterodine ranitidine
Lanoxine simvastatine
acetylsalicylic acid
Imaging (MR) Enlarged pituitary gland
1.4 9 1 9 1 cm
Enlargement of the stalk
and the posterior part
of the pituitary gland
Normal Normal pituitary gland
leptomeningeal
metastases
NA not available, Data in grey—meaning a value below the reference interval
a Female: 35.4–256 lg/dL, Male: 160–449 lg/dL; b Morning: 5.15–27.6 lg/dL, Afternoon: 1.85–15.4 lg/dL; c Female: Follicular 3–13 mU/
mL, ovulatory 5–22 mU/mL, luteal 2–8 mU/mL, after menopause [26 mU/mL. Male: 1–12 mU/mL; d Female: Follicular 2–13 mU/mL, peri-
ovulatory 14–96 mU/mL, luteal 1–11 mU/mL, postmenopausal 8–59. Male: 1–9 mU/mL
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gonadal axes. The diagnosis of hypophysitis was confirmed
with a magnetic resonance of the pituitary gland. There
was no evidence of brain metastases. Ipilimumab was
discontinued and hormonal substitution was started
(L-thyroxine, hydrocortisone and dehydroepiandrosterone).
Currently, the patient is still on hormonal replacement
therapy. She still needs periodically laboratory follow-up
and radiographic imaging because of a persistent secondary
adrenal insufficiency.
Regarding her melanoma, the patient is still disease-free
and in follow-up.
Hypophysitis with failure of the ACTH axis
This patient, a 31-year-old man, was diagnosed with a
superficial spreading melanoma on the left flank in Sep-
tember 2010. The pathologic examination showed follow-
ing results: Breslow thickness 2.3 mm, Clark level 4 and a
focal ulceration of 0.3 mm. There was no invasion of the
vessels and no positive cutting edges. A sentinel procedure
was performed and showed metastatic invasion of 3 nodes.
A broad excision was performed. The final stage was
pT3bN2M0 (stage IIIB).
Ipilimumab was started in an adjuvant study setting
(10 mg/kg). Two months after administration of the fourth
cycle (20 weeks after initiation of ipilimumab), the patient
developed fatigue, muscle weakness and pain at both
calves. Hormonal investigations showed a normal thyroid
function, normal gonadal function and adequate IGF1 level
but undetectable ACTH, cortisol and low DHEAS levels,
typical for an isolated failure of the ACTH axis. Ipi-
limumab was discontinued and substitution with hydro-
cortisone was started. After just 1 month on treatment, the
patient developed a gastroenteritis with hypotension and
hypokalaemia possibly suggesting an adrenal crisis, even if
hyperkalaemia should be more typically expected. The
natremia was normal. After 6 months, there was still no
recovery of the ACTH production and currently the patient
still needs substitution therapy.
Seventeen months after finishing therapy with ipi-
limumab, the patient presented a locoregional relapse,
treated with surgical resection. Several new relapses have
been diagnosed meanwhile for which he is treated
surgically.
Hypophysitis with hypothyroidism and secondary
adrenal insufficiency
In 2005 an 81-year-old man developed a lentigo maligna of
the scalp completely resected. During the next 2 years, the
patient relapsed four times with in-transit metastases sec-
ondary to the melanoma of the scalp. In February 2008, he
developed metastatic disease and systemic treatment was
started. Chemotherapy with dacarbazine was prescribed
(200 mg/days, d1–d5, q4w). After 3 cycles of chemother-
apy, the patient presented with progressive disease. Second
line treatment with a cisplatinum-chemotherapy-doublet
was started. After six cycles, the patient had stable disease,
and treatment was stopped.
Two years later (May 2010), the patient developed a
metastatic lymph node at the right site of his neck. Staging
with PET-CT confirmed metastatic disease (a micronodule
at the right upper lung lobe and one at the left under lobe).
After resection of the pathologic node, third line therapy
with ipilimumab (3 mg/kg) was started. After only three
cycles, the patient complained about progressive lethargy
and adynamia. There was no fever, diarrhoea, palpitations
or alopecia. He also had mild headache without photo- or
phonophobia. MRI could not argument an image of
hypophysitis. On the other hand, CT thorax and abdomen
showed diffuse lung and liver metastases and voluminous
bronchial lymph nodes bilateral. Hormonal investigation
demonstrated hypothyroidism and secondary adrenal
insufficiency. Ipilimumab was discontinued and substitu-
tion therapy with hydrocortisone and L-thyroxine was
started. Treatment resulted in a rapid improvement of the
clinical symptoms. Unfortunately, the patient developed a
very fast progression of his disease and best supportive
care was started. He finally died 3 months after the start of
ipilimumab. Substitution therapy was needed during the
whole period of survival.
Hypophysitis with secondary adrenal deficiency
and thyroid dysfunction
A 78-year-old male patient was diagnosed in April 2012
with a metastatic melanoma, with lung and liver metastasis.
First line chemotherapy, DTIC (200 mg/m2, d1–D5,
q3w) was started. After 3 cycles, the patient presented with
progressive disease. Second line therapy with ipilimumab
(3 mg/kg) was initiated in December 2012. After the sec-
ond infusion, the patient complained about unilateral
parietal palpitating headache as well as mild photo- and
phonophobia. The complaints improved by administration
of corticoids. Biochemical evaluation revealed a hypoph-
ysitis with secondary adrenal deficiency and thyroid dys-
function in January 2013. Further therapy with ipilimumab
was discontinued and treatment with hydrocortisone was
started. To date, 7 months after the diagnosis of hypoph-
ysitis, the patient still needs substitution therapy with
methylprednisolone and levothyroxine.
Two weeks after discontinuation of ipilimumab, brain
metastases were diagnosed. The patient underwent radio-
therapy. We chose not to start any other systemic treat-
ment. The patient is followed with best supportive care.
Endocrine (2014) 47:878–883 881
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Discussion
The side effects caused by ipilimumab can be severe. We
report a series of 4 cases of hypophysitis secondary to the
administration of ipilimumab in a cohort of 39 patients
(10 %) with advanced melanoma.
Hypophysitis secondary to ipilimumab administration,
first reported in 2003 [13], is now well described, but the
mechanism of pituitary injury remains unknown. It is still
unclear whether the effects result from T cells specifically
acting against antigens shared by tumour and normal cells
or from the concomitant activation of multiple T cell
populations with separate anti-host and anti-tumour activ-
ity [11–13].
In our series, there is no relation with the dose admin-
istered, even though some reports suggest a dose-dependent
effect not only on efficacy of the drug but also on toxicity,
with more side effects occurring at higher doses [14]. Some
phase II data suggest that patients experiencing an irAE
have a higher chance of an anti-tumour response to ipi-
limumab and higher irAEs incidences have been associated
with longer survival. However, disease control and survival
benefits have also been seen in patients without irAEs.
Recently, data have been published on the association
between the occurrence of irAEs and ipilimumab efficacy
based on the Expanded Access Program in Italy [15]. The
results of the exploratory analysis suggest that the efficacy
of ipilimumab is not related to the occurrence of irAEs.
Disease survival and benefits with ipilimumab were similar
among patients with or without irAEs [15]. Furthermore,
recently, data have been published on the use of ipilimumab
in the elderly. Despite risk of serious adverse events, ipi-
limumab is considered a feasible treatment option [14].
Mostly, the immune-related adverse events can be
handled with the administration of corticosteroids. High-
dose corticosteroids for treatment of the irAEs do not
appear to impair the anti-tumour response [17, 18]. It is
generally accepted that the hypophysitis is not reversible.
Long-term, even lifelong hormone therapy will frequently
be required [16]. The incidence of hypophysitis due to i-
pilimumab has been reported to range from 0 to 17 % in
clinical trials for melanoma and for renal cell carcinoma.
Anatomic evaluation of the pituitary gland with MRI in
conjunction with serial biochemical evaluations may be
helpful in monitoring therapy-induced hypophysitis and
preventing life-threatening side effects [19, 20]. It may also
be helpful in the differential diagnosis of melanoma to
consider both brain metastasis and hypophysitis as auto-
immune reaction. In our series, the posterior pituitary
function remained normal in all the cases in accordance
with the literature, suggesting a possible predilection of
ipilimumab for corticotrophic and probably thyrotrophic
cells [21].
For moderate grade 2 immune-mediated toxicities,
treatment with ipilimumab should be discontinued and
should not be resumed until toxicity is grade 1 or less.
Corticosteroids (prednisone 0.5 mg/kg/day or equivalent)
should be started if symptoms do not resolve within a
week. For patients with severe or life-threatening grade 3/4
toxicities, treatment with ipilimumab should be perma-
nently discontinued and high doses of corticosteroids
(prednisone 1 to 2 mg/kg/day or equivalent) are indicated.
When symptoms diminish to grade 1 or less, steroids can
be gradually tapered and stopped over at least one month
[9]. Several case-reports have shown that even after sig-
nificant immune-mediated toxicities, re-induction of treat-
ment may be possible. This permits ongoing therapy with
long-term survival. However, restarting ipilimumab has to
be discussed individually with the patient to evaluate risk–
benefit versus other treatment options (Table 3).
Ipilimumab associated irAEs are consistent with its
immune-based mechanism of action. Most frequently the
irAEs occur during the induction phase of treatment
(0–12 weeks) and when managed with treatment guidelines
comprising vigilant monitoring and high-dose corticoste-
roids, the median time to resolution is approximately
6 weeks for grade 2 irAEs and 8 weeks for grade 3 and 4
irAEs [22].
To conclude, in this series, we report 4 cases of a severe
endocrine adverse event during treatment with ipilimumab.
Of all patients treated with ipilimumab at our institution,
10 % presented with a hypophysitis with involvement of
one or more pituitary axes. We document the cases with
detailed clinical information regarding symptoms and rel-
evant biochemical values. For all patients, except for
patient 4, we report the biochemical values by diagnosis
and at follow-up. Due to a quick deterioration of the
Table 3 Management of hypophysitis toxicity in patients receiving
ipilimumab
Toxicity
Grade
Ipilimumab
discontinuation
Management
1 No Asymptomatic or mild symptoms;
clinical or diagnostic observations
only; intervention not indicated
2 Yes If symptoms do not resolve within
1 week of ipilimumab
discontinuation, start glucocorticoids
(such as, prednisone 0.5 mg/kg/day)
3 Yes Start high-dose glucocorticoids (such
as, prednisone 1–2 mg/kg/day). When
symptoms diminish to grade 1 or less,
taper gradually the steroids over the
course of 1–2 months
4 Yes Same as for grade 3
Legend Management of hypophysitis toxicity related to ipilimumab
882 Endocrine (2014) 47:878–883
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clinical situation, we did not evaluate the hormonal values
after initiation of therapy for patient 4. Administration of
corticosteroid was continued only based on symptoms and
clinical presentation. The problem of hypophysitis can be
associated with severe headache besides the panhypopitu-
itarism as described. This was not the case for any of our
patients. If a severe and persistent headache is present,
high-dose corticosteroids are recommended. However, due
to the adverse events related to the use of high-dose cor-
ticosteroids, such as induction of an extreme Cushing status
as well as hypertension, osteoporosis, aseptic necrosis and
diabetes mellitus type 2 on the long term, this is not
standard for every patient with a hypophysitis. For all
patients, we report low values of ACTH and cortisol at
diagnosis indicating a secondary adrenal insufficiency. Due
to the palliative setting of all patients, this was not con-
firmed with an ACTH stimulation test. For patient 1, 3 and
4, we report low TSH as well. The absence of a few data
can be considered as a limitation of our series, only due to
the retrospective character of the data reporting.
Nevertheless, endocrine side effects associated with the
immunotherapy will need more clinical awareness in the
near-coming future. Several clinical trials are ongoing and
even more trials will be started to further evaluate the role
of immunotherapy in metastatic melanoma and other can-
cer types; to improve survival rates and maybe even cure
for this highly aggressive disease. Still, new treatments
may cause new side effects. It will be an inevitable chal-
lenge to recognize and treat the adverse events on an early
stage without compromising the possible beneficial effects
of the new treatments.
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